PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
39.63
-1.02 (-2.51%)
May 6, 2025, 12:20 PM EDT - Market open
PTC Therapeutics Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for PTC Therapeutics stock have an average target of 63.92, with a low estimate of 42 and a high estimate of 113. The average target predicts an increase of 61.29% from the current stock price of 39.63.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for PTC Therapeutics stock from 13 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 5 | 5 | 6 | 6 | 6 | 6 |
| Hold | 3 | 3 | 2 | 3 | 3 | 3 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Strong Sell | 2 | 2 | 2 | 2 | 2 | 2 |
| Total | 13 | 13 | 13 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $65 | Buy | Reiterates | $65 | +64.02% | Apr 22, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $78 → $75 | Buy | Maintains | $78 → $75 | +89.25% | Mar 31, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $72 → $78 | Buy | Maintains | $72 → $78 | +96.82% | Mar 14, 2025 |
| B of A Securities | B of A Securities | Sell → Hold Upgrades $41 → $55 | Sell → Hold | Upgrades | $41 → $55 | +38.78% | Mar 11, 2025 |
| Scotiabank | Scotiabank | Hold Initiates $55 | Hold | Initiates | $55 | +38.78% | Mar 7, 2025 |
Financial Forecast
Revenue This Year
734.53M
from 806.78M
Decreased by -8.96%
Revenue Next Year
857.10M
from 734.53M
Increased by 16.69%
EPS This Year
-3.12
from -4.73
EPS Next Year
-2.42
from -3.12
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 812.7M | 1.0B | 1.7B | ||
| Avg | 734.5M | 857.1M | 1.1B | ||
| Low | 642.5M | 708.7M | 816.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.7% | 39.1% | 93.2% | ||
| Avg | -9.0% | 16.7% | 29.7% | ||
| Low | -20.4% | -3.5% | -4.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7.22 | 5.93 | 9.50 | ||
| Avg | -3.12 | -2.42 | 0.40 | ||
| Low | -7.44 | -7.22 | -6.32 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.